FORMULATION AND IN-VITRO EVALUATION OF MUCOADHESIVE DOSAGE FORM CONTAINING LEVOSALBUTAMOL SULPHATE

The buccal region offers an attractive route of administration for systemic drug delivery. The mucosa has a rich blood supply and provides rapid absorption for drugs than oral route. The Levosalbutamol sulphate is a β adreno-receptor agonist used for the maintenance, treatment of chronic asthma attacks and to relieve Chronic obstructive pulmonary diseases (COPD) Because of poor bioavailability of Levosalbutamol sulphate by oral route, there is a need to increase its bioavailability by formulating it into buccal dosage forms. The main objective of study was to formulate and evaluate buccal tablets of Levosalbutamol sulphate. The tablets were prepared by direct compression method. The tablets were evaluated based on their physical characteristics like, weight variation, thickness, hardness; their mechanical properties are found within the prescribed limits. Swelling index of all the formulations were between ranges of 18.56±0.55 to 89.31±0.07. Surface pH, friability, like in vitro residence time and their evaluations like, drug content uniformity are found within the ranges, the ranges of (F7F12) and in vitro study shows drug release from 71.25% to 99.24%, among these the formulation (F8) shown highest drug release of 99.24±1.00% at the end of 8 hours. The FTIR study reveals that there was no interaction between API and excipients. It was observed that all preformulation and formulation parameters were acceptable with reasonable limits of standards required for buccal tablets which may enhance the absorption of drug with increased residence time in buccal cavity avoiding first pass metabolism also may leads to